摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

<2-14C>Carbostyril | 114255-05-9

中文名称
——
中文别名
——
英文名称
<2-14C>Carbostyril
英文别名
1H-quinolin-2-one
<2-14C>Carbostyril化学式
CAS
114255-05-9
化学式
C9H7NO
mdl
——
分子量
147.15
InChiKey
LISFMEBWQUVKPJ-FOQJRBATSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    29.1
  • 氢给体数:
    1
  • 氢受体数:
    1

文献信息

  • [EN] MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS<br/>[FR] PEPTIDES MACROCYCLIQUES ACTIFS CONTRE LE VIRUS DE L'HEPATITE C
    申请人:BOEHRINGER INGELHEIM CA LTD
    公开号:WO2000059929A1
    公开(公告)日:2000-10-12
    The present invention covers macrocyclic compounds of formula (I) active in-vitro and in cellular assays against the NS3 protease of the hepatitis C virus wherein W is CH or N; R21 is H, halo, C¿1-6? alkyl, cycloalkyl, haloalkyl, C1-6 alkoxy, cycloalkoxy, hydroxy, or N(R?23)¿2, wherein each R23 is independently H, C¿1-6? alkyl or cycloalkoxy; and R?22¿ is H, halo, C¿1-6? alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, C1-6 thioalkyl, C1-6 alkoxy, C3-6 cycloalkoxy, C2-7 alkoxyalkyl, C3-6 cycloalkyl, C6 or 10 aryl or Het, wherein Het is a five-, six-, or seven-membered saturated or unsaturated heterocycle containing from one to four heteroatoms selected from nitrogen, oxygen and sulfur; said cycloalkyl, aryl or Het being substituted with R?24¿, wherein R24 is H, C¿1-6? alkyl, C3-6 cycloalkyl, C1-6 alkoxy, C3-6 cycloalkoxy, NO2, N(R?25)¿2, NH-C(O)-R25; or NH-C(O)-NH-R25, wherein each R25 is independently: H, C¿1-6? alkyl or C3-6 cycloalkyl; or R?24¿ is NH-C(O)-OR26 wherein R26 is C¿1-6? alkyl or C3-6 cycloalkyl; R?3¿ is hydroxy, NH¿2?, or a group of formula -NH-R?31¿, wherein R31 is C6 or 10 aryl, heteroaryl, -C(O)-R32, -C(O)-OR32 or -C(O)-NHR32, wherein R32 is: C¿1-6? alkyl or C3-6 cycloalkyl; D is a 5 to 10-atom saturated or unsaturated alkylene chain optionally containing one to three heteroatoms independently selected from: O, S, or N-R?41¿, wherein R41 is H, C¿1-6? alkyl, cycloalkyl or -C(O)-R?42¿, wherein R42 is C¿1-6? alkyl, cycloalkyl or C6 or 10 aryl; R?4¿ is H or from one to three substituents at any carbon atom of said chain D, said substituent independently selected from the group consisting of: C¿1-6? alkyl, C1-6 haloalkyl, C1-6 alkoxy, hydroxy, halo, amino, oxo, thio or C1-6 thioalkyl, and A is an amide of formula -C(O)-NH-R?5¿, wherein R5 is selected from the group consisting of: C¿1-8? alkyl, C3-6 cycloalkyl, C6 or 10 aryl or C7-16 aralkyl; or A is a carboxylic acid or a pharmaceutically acceptable salt or ester thereof.
    本发明涵盖了式(I)的大环化合物,该化合物在体外和细胞试验中对丙型肝炎病毒的NS3蛋白酶具有活性,其中W为CH或N; R21为H,卤素,C1-6烷基,环烷基,卤代烷基,C1-6烷氧基,环烷氧基,羟基或N(R23)2,其中每个R23独立地为H,C1-6烷基或环烷氧基; R22为H,卤素,C1-6烷基,C3-6环烷基,C1-6卤代烷基,C1-6代烷基,C1-6烷氧基,C3-6环烷氧基,C2-7烷氧基烷基,C3-6环烷基,C6或10芳基或Het,其中Het是含有1至4个从氮,氧和选择的杂原子的五元,六元或七元饱和或不饱和杂环; 所述的环烷基,芳基或Het被R24取代,其中R24为H,C1-6烷基,C3-6环烷基,C1-6烷氧基,C3-6环烷氧基,NO2,N(R25)2,NH-C(O)-R25; 或NH-C(O)-NH-R25,其中每个R25独立地为:H,C1-6烷基或C3-6环烷基; 或R24为NH-C(O)-OR26,其中R26为C1-6烷基或C3-6环烷基; R3为羟基,NH2或式-NH-R31的基团,其中R31为C6或10芳基,杂芳基,-C(O)-R32,-C(O)-OR32或-C(O)-NHR32,其中R32为:C1-6烷基或C3-6环烷基; D为5至10个原子的饱和或不饱和烷基链,可选地包含从O,S或N-R41中独立选择的1至3个杂原子,其中R41为H,C1-6烷基,环烷基或-C(O)-R42,其中R42为C1-6烷基,环烷基或C6或10芳基; R4为H或在链D的任何碳原子上的1至3个取代基,所述取代基独立地选择自以下群:C1-6烷基,C1-6卤代烷基,C1-6烷氧基,羟基,卤素,基,氧代,代或C1-6代烷基; A为式-C(O)-NH-R5的酰胺,其中R5选择自以下群:C1-8烷基,C3-6环烷基,C6或10芳基或C7-16芳基烷基; 或A为羧酸或其药学上可接受的盐或酯。
  • Macrocyclic peptides active against the hepatitis C virus
    申请人:Boehringer Ingelheim (Canada) Ltd.
    公开号:US20040002448A1
    公开(公告)日:2004-01-01
    The present invention covers macrocyclic compounds of formula I active in-vitro and in cellular assays against the NS3 protease of the hepatitis C virus. 1 wherein W, R 21 , R 22 , R 3 , R 4 , D and A are as defined herein, or a pharmaceutically acceptable salt or ester thereof.
    本发明涵盖了公式I的大环化合物,该化合物在体外和细胞测定中对丙型肝炎病毒的NS3蛋白酶具有活性。 其中,W,R21,R22,R3,R4,D和A如此处所定义,或其药学上可接受的盐或酯。
  • Macrocyclic peptides inhibiting the hepatitis C virus ns3 protease
    申请人:BOEHRINGER INGELHEIM (CANADA) LTD.
    公开号:EP1437362A1
    公开(公告)日:2004-07-14
    The present invention covers macrocyclic compounds of formula I active in-vitro and in cellular assays against the NS3 protease of the hepatitis C virus. wherein W is CH or N; R21 is H, halo, C1-6 alkyl, cycloalkyl, haloalkyl, C1-6 alkoxy, cycloalkoxy, hydroxy, or N(R23)2, wherein each R23 is independently H, C1-6 alkyl or cycloalkoxy; and R22 is H, halo, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, C1-6 thioalkyl, C1-6 alkoxy, C3-6 cycloalkoxy, C2-7 alkoxyalkyl, C3-6 cycloalkyl, C6 or 10 aryl or Het, wherein Het is a five-, six-, or seven-membered saturated or unsaturated heterocycle containing from one to four heteroatoms selected from nitrogen, oxygen and sulfur; said cycloalkyl, aryl or Het being substituted with R24, wherein R24 is H, C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkoxy, C3-6 cycloalkoxy, NO2, N(R25)2, NH-C(O)-R25; or NH-C(O)-NH-R25, wherein each R25 is independently: H, C1-6 alkyl or C3-6 cycloalkyl; or R24 is NH-C(O)-OR26 wherein R26 is C1-6 alkyl or C3-6 cycloalkyl; R3 is hydroxy, NH2, or a group of formula - NH-R31, wherein R31 is C6 or 10 aryl, heteroaryl, -C(O)-R32, -C(O)-OR32 or -C(O)-NHR32, wherein R32 is: C1-6 alkyl or C3-6 cycloalkyl; D is a 5 to 10-atom saturated or unsaturated alkylene chain optionally containing one to three heteroatoms independently selected from: O, S, or N-R41, wherein R41 is H, C1-6 alkyl, cycloalkyl or -C(O)-R42, wherein R42 is C1-6 alkyl, cycloalkyl or C6 or 10 aryl; R4 is H or from one to three substituents at any carbon atom of said chain D, said substituent independently selected from the group consisting of: C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, hydroxy, halo, amino, oxo, thio or C1-6 thioalkyl, and A is an amide of formula -C(O)-NH-R5, wherein R5 is selected from the group consisting of: C1-8 alkyl, C3-6 cycloalkyl, C6 or 10 aryl or C7-16 aralkyl; or A is a carboxylic acid or a pharmaceutically acceptable salt or ester thereof.
    本发明包括在体外和细胞检测中对丙型肝炎病毒 NS3 蛋白酶具有活性的式 I 大环化合物。 其中 W 是 CH 或 N;R21 是 H、卤代、C1-6 烷基、环烷基、卤代烷基、C1-6 烷氧基、环烷氧基、羟基或 N(R23)2,其中每个 R23 独立地是 H、C1-6 烷基或环烷氧基;R22 是 H、卤素、C1-6 烷基、C3-6 环烷基、C1-6 卤代烷基、C1-6 代烷基、C1-6 烷氧基、C3-6 环烷氧基、C2-7 烷氧基烷基、C3-6 环烷基、C6 或 10 芳基或 Het,其中 Het 是含有一至四个选自氮、氧和的杂原子的五元、六元或七元饱和或不饱和杂环;所述环烷基、芳基或 Het 被 R24 取代,其中 R24 是 H、C1-6 烷基、C3-6 环烷基、C1-6 烷氧基、C3-6 环烷氧基、NO2、N(R25)2、NH-C(O)-R25 或 NH-C(O)-NH-R25,其中每个 R25 独立地是:H、C1-6 烷基或 C3-6 环烷基;或 R24 是 NH-C(O)-OR26,其中 R26 是 C1-6 烷基或 C3-6 环烷基;R3 是羟基、NH2 或式-NH-R31 的基团,其中 R31 是 C6 或 10 芳基、杂芳基、-C(O)-R32、-C(O)-OR32 或-C(O)-NHR32,其中 R32 是:C1-6烷基或C3-6环烷基; D是5至10原子的饱和或不饱和亚烷基链,可任选含有1至3个独立选自以下的杂原子: O、S或N-R41,其中R41是H、C1-6烷基、环烷基或-C(O)-R42,其中R42是C1-6烷基、环烷基或C6或10芳基; R4是H或在所述链D的任一碳原子上的1至3个取代基,所述取代基独立选自以下组成的组:C1-6烷基、C1-6卤代烷基、C1-6烷氧基、羟基、卤代、基、氧代、代或 C1-6 代烷基,以及 A 是式-C(O)-NH-R5 的酰胺,其中 R5 选自由下列组成的组C1-8 烷基、C3-6 环烷基、C6 或 10 芳基或 C7-16 芳烷基;或 A 是羧酸或其药学上可接受的盐或酯。
  • MACROCYCLIC PEPTIDES INHIBITING THE HEPATITIS C VIRUS NS3 PROTEASE
    申请人:BOEHRINGER INGELHEIM (CANADA) LTD.
    公开号:EP1169339A1
    公开(公告)日:2002-01-09
  • US6608027B1
    申请人:——
    公开号:US6608027B1
    公开(公告)日:2003-08-19
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-(+)-5,5'',6,6'',7,7'',8,8''-八氢-3,3''-二叔丁基-1,1''-二-2-萘酚,双钾盐 (S)-盐酸沙丁胺醇 (S)-溴烯醇内酯 (S)-7,7-双[(4S)-(苯基)恶唑-2-基)]-2,2,3,3-四氢-1,1-螺双茚满 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2-N-Fmoc-氨基甲基吡咯烷盐酸盐 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-7,7-双[(4S)-(苯基)恶唑-2-基)]-2,2,3,3-四氢-1,1-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-3-(叔丁基)-4-(2,6-二异丙氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-3,3''-双([[1,1''-联苯]-4-基)-[1,1''-联萘]-2,2''-二醇 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-2,2'',3,3''-四氢-6,6''-二-9-菲基-1,1''-螺双[1H-茚]-7,7''-二醇 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (6,6)-苯基-C61己酸甲酯 (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,5R)-3,3a,8,8a-四氢茚并[1,2-d]-1,2,3-氧杂噻唑-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aS,8aR)-2-(吡啶-2-基)-8,8a-二氢-3aH-茚并[1,2-d]恶唑 (3aS,3''aS,8aR,8''aR)-2,2''-环戊二烯双[3a,8a-二氢-8H-茚并[1,2-d]恶唑] (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (3S,3aR)-2-(3-氯-4-氰基苯基)-3-环戊基-3,3a,4,5-四氢-2H-苯并[g]吲唑-7-羧酸 (3R,3’’R,4S,4’’S,11bS,11’’bS)-(+)-4,4’’-二叔丁基-4,4’’,5,5’’-四氢-3,3’’-联-3H-二萘酚[2,1-c:1’’,2’’-e]膦(S)-BINAPINE (3-三苯基甲氨基甲基)吡啶 (3-[(E)-1-氰基-2-乙氧基-2-hydroxyethenyl]-1-氧代-1H-茚-2-甲酰胺) (2′′-甲基氨基-1,1′′-联苯-2-基)甲烷磺酰基铝(II)二聚体 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,4S)-Fmoc-4-三氟甲基吡咯烷-2-羧酸 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,3R)-3-(叔丁基)-2-(二叔丁基膦基)-4-甲氧基-2,3-二氢苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环